W
hen the Beers Criteria for potentially inappropriate medication use in elderly adults were first introduced 20 years ago, a select number of psychotropic medications were included, primarily because of their sedating effects: long-acting benzodiazepines, short-acting benzodiazepines above a low dosage, amitriptyline, and doxepin. 1 With each subsequent revision of the criteria, the list of psychotropic medications has grown, along with the evidence of associated risks [2] [3] [4] [5] ; the 2015 version now includes virtually every class of psychotropic medication. 6 The potential harms for older adults are particularly troubling given growing evidence that a significant proportion of psychotropic prescribing in older adults occurs in the absence of significant psychiatric symptoms 7 or a clearly defined mental health disorder. 8, 9 As the number of psychotropic medications in the Beers Criteria increased, opioids were not featured prominently, but their use is now included as potentially inappropriate in a measure of central nervous system (CNS) polypharmacy, defined as three or more prescriptions from the following classes: antipsychotics, benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonist hypnotics (NBRAs), tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and opioids. 6 This revision follows evidence that CNS polypharmacy (opioids included) is associated with risk of falls 5 and cognitive decline. 10 In light of the opioid epidemic, there is now even greater attention focused on combined use of CNS medications. Co-prescribing of opioids and benzodiazepines is a particular cause for concern given their common role together in pharmaceutical overdose deaths. The risk of mortality increases with the dose of benzodiazepine prescribed. 11 The U.S. Food and Drug Administration (FDA) recently issued a black box warning advising of slowed breathing and death caused by co-prescribing opioids with CNS depressants, including benzodiazepines, NBRAs, and antipsychotics, 12 all of which are included in the Beers polypharmacy measure.
The use of individual psychotropic medication classes and prescription opioids has increased in older adults in the United States, 13, 14 with CNS polypharmacy visits for older adults more than doubling between 2004-06 and 2011-13. 15 Although polypharmacy has risen overall, it is unclear which specific medication classes account for this growth. To address CNS polypharmacy, it is important to understand which medications and medication combinations are most common. The present study used data from the National Ambulatory Medical Care Survey (NAMCS), a nationally representative survey of visits to office-based physicians in the United States, to better characterize the relative contribution of specific medication classes to CNS polypharmacy and how this has changed over time.
METHODS

Sample
The analysis used data from NAMCS from 2004 through 2013, the most recent year available. NAMCS is a national probability sample survey of office-based and community health center-based physicians conducted annually and designed to "provide objective, reliable information about the provision and use of ambulatory medical care services in the United States". 16 Non-federally employed physicians engaged in office-based practice are sampled from the American Medical Association and American Osteopathic Association master files; physicians in anesthesiology, pathology, and radiology are excluded.
Throughout the year, each participating physician is assigned a 1-week reporting period, with data collected from a random sample of visits during that week. For very small practices, every visit may be included; for large practices, 10% of visits may be included. 17 Encounters such as house calls or in institutional settings (e.g., nursing homes) are not included. For survey years before 2012, physicians, their office staff, or field representatives of the U.S. Census Bureau recorded data for selected visits on a standardized form. Beginning in 2012, NAMCS implemented computer-assisted data collection, which Census staff primarily performed. The 2013 NAMCS public use data file does not include visits to community health centers, so such visits from other years were excluded from analysis, as NAMCS recommends. Additional technical information concerning the survey sampling design and nonresponse adjustment is provided elsewhere. 17 The current analysis was drawn from visits of individuals aged 65 and older to all outpatient providers (N = 97,910).
Medications and Other Visit Characteristics
Survey data included up to eight medications prescribed, ordered, supplied, administered, or continued during each visit. Although the 2012 and 2013 surveys included up to 10 medications, this analysis used only the first eight listed medications to be consistent across all years. The 2015 American Geriatrics Society Beers Criteria includes use of three or more CNS medication classes as potentially inappropriate: antipsychotics, benzodiazepines, NBRAs, TCAs, SSRIs, and opioids. Medications in NAMCS are assigned to therapeutic classes according to Lexicon Plus, a proprietary database of Cerner Multum, Inc. 17 A visit was classified as meeting the Beers CNS polypharmacy criteria if it included three or more medications from any of these classes.
For this analysis, basic demographic data collected, such as patient age, sex, and race and ethnicity were also included. NAMCS classifies physicians into 15 specialty groups; this analysis includes visits to all physicians, categorized as family medicine, internal medicine, psychiatry, or other medical specialties.
Statistical Methods
Survey years (2004-06, 2007-10, 2011-13) were grouped as NAMCS recommends to produce more-reliable annual visit rate estimates. 18 All analyses were completed using survey design elements for visit weight, clustering within physician practice, and stratification to allow national inferences. 17 First, all older adult visits across the study period were compared according to basic demographic and visit characteristics using difference in proportion tests. Next, the relative contribution of each medication class to CNS polypharmacy overall was determined for the most-recent time period (2011-13). Finally, the contribution of these medication classes to CNS polypharmacy during each time period was determined, and logistic regression was used to determine how odds of use for each class changed over time. For example, an odds ratio of 2.0 means that a visit in 2013 had twice the odds of that medication class contributing to CNS polypharmacy visits of a visit in 2004. Regression models were adjusted for age, sex, and race and ethnicity. Because the Beers polypharmacy measure does not include diagnosis-based exclusions, the analyses were not adjusted for clinical diagnosis. Analyses were conducted in Stata version 13.1 (Stata Corp., College Station, TX) using two-sided tests with a = .05.
RESULTS
Background characteristics of NAMCS visits by adults aged 65 and older are presented in Table 1 . During the study period, there were 97,910 office visits, 1,062 of which met criteria for CNS polypharmacy. As reported previously, between 2011 and 2013, there was polypharmacy at 1.3% of all outpatient encounters of older adults. 15 Opioids were the most commonly prescribed medication group of CNS polypharmacy encounters (76.2%), followed by benzodiazepines (61.8%) and SSRIs (51.5%) ( Table 2) . Although opioids and benzodiazepines were the most-common medications in polypharmacy visits, they were also most commonly used with each other. Of individuals with CNS polypharmacy that included an opioid, 53.3% were co-prescribed a benzodiazepine; of individuals with CNS polypharmacy that included a benzodiazepine, 66.0% were co-prescribed an opioid. Between 2011 and 2013, this opioid and benzodiazepine co-prescribing occurred at approximately 1.50 million visits (95% confidence interval (CI) = 1.23-1.78 million) annually. Opioid co-prescribing was the least common of CNS polypharmacy that included an antipsychotic, just 35.9% of those prescribed an antipsychotic medication were also prescribed an opioid. Overall, TCAs were the least common class, prescribed at just 10.8% of CNS polypharmacy encounters overall and the least commonly prescribed with each other medication class.
In CNS polypharmacy encounters, opioids were the most-common medication class and the only class in which the odds of that medication class contributing to CNS polypharmacy visits increased from 2004 to 2013 (adjusted odds ratio (aOR) = 2.15, 95% CI = 1.19-3.91, P = .01) ( Table 3) . Although the odds of benzodiazepines as a polypharmacy component decreased during the study period, they were still the second-most-commonly prescribed medication group. The odds of SSRIs, NBRAs, or antipsychotics as a polypharmacy component were unchanged over the study period. TCA use decreased significantly, falling from 23.9% to 10.8% (aOR = 0.31, 95% CI = 0.15-0.66, P = .002).
DISCUSSION
Opioids are the most-common component of CNS polypharmacy in older adults in the United States and account for the greatest share of the overall increase in CNS polypharmacy. Although the odds of benzodiazepine use decreased slightly during the study interval, benzodiazepines remained the second-most-common polypharmacy component. Although the Beers CNS polypharmacy measure cites the risk of falls as its primary rationale, the recent FDA black box warning primarily concerns risk of respiratory suppression and death due to concomitant use of opioids and other CNS depressants, most notably benzodiazepines. More than 30% of overdose deaths of U.S. veterans related to opioids also include benzodiazepines. 19 Therefore, it is particularly troubling that opioids and benzodiazepines are the two medication groups that most contribute to CNS polypharmacy in older adults.
From 2004 to 2013, although polypharmacy grew overall, the odds of SSRIs, NBRAs, or antipsychotics as a polypharmacy component were unchanged. This is consistent with previous analyses suggesting growth of these individual medication classes. 15, [20] [21] [22] Although the opioidspecific growth may be attributed to the emphasis on treatment of pain, growth of other medication classes may reflect polypharmacy used to target other specific indication (e.g., depression) or more-widespread use of medications for multiple off-label indications. For example, greater use of quetiapine may reflect indication expansion This study has several limitations. NAMCS does not account for whether a prescribed medication is taken regularly versus as needed, so it is possible that the extent of regular use was overestimated. Because the data were multiple cross-sectional samples, outcomes associated with medication use cannot be reported on. Because NAMCS is a survey of office-based medical practice, it does not include physicians practicing in other settings or nonphysician providers. In addition, being based on a survey of U.S. physicians, the results examine trends only in the U.S. healthcare system and do not generalize internationally. Physician nonresponse might have introduced bias into the results, but the survey weights that NAMCS designed account for this to produce unbiased national estimates. 16 Finally, in 2012, NAMCS began using Census field representatives rather than physician office staff to conduct data collection. NAMCS reports that these changes did not affect diagnosis results, although the number of medications reported decreased, for which National Center for Health Statistics (NCHS) NCHS staff "have researched . . .
[all] possible contributing factors" without clear explanation, 16 which suggests that the current study results may have underestimated the actual increase in CNS polypharmacy visits.
In light of the serious health consequences for older adults associated with CNS polypharmacy, potentially including falls and death, it is troubling that such prescribing continues to rise. 15 Although this combination of medications may be appropriate in select populations, use should be considered only after careful assessment of the risks, benefits, and alternatives. Public attitudes have grown more favorable toward psychotropic medications, 24 and older adults have become more open to mental health treatment. Although this may lead to better treatment for some older adults, it may also lead to inappropriate overtreatment for others. In light of the recent FDA warning, co-prescribing of opioids and benzodiazepines is particularly troubling. It is critical to reduce this common and potentially lethal prescribing. There have been promising studies implementing structured algorithms to reduce polypharmacy, including psychotropic medications, demonstrating success in discontinuing medication without adverse effects, often with significant improvement in health outcomes. 25 Direct patient education about the harms potentially associated with medications that contribute to CNS polypharmacy may also lead some people to initiate discussions about appropriate prescribing, as demonstrated with chronic benzodiazepine use. 26 Lastly, improving access to evidence-based nonpharmacological treatments for insomnia, anxiety, or pain might also limit polypharmacy. In treatment of older adults, the adage "less is more" holds true, and further work is needed to emphasize deprescribing in older adults. Conflict of Interest: MO has been a principal investigator on grants to Columbia University from Sunovion Pharmaceuticals and Janssen Pharmaceuticals Author Contributions: All authors: study concept and design, interpretation of date, preparation of manuscript. DTM: Data analysis.
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